The prices were made possible by the Inflation Reduction Act, which granted the health secretary the authority to negotiate on behalf of Medicare.
Listen to this article · 1:39 min Learn more
- Share full article
By Noah Weiland and Rebecca Robbins
Aug. 15, 2024, 10:10 a.m. ET
The Biden administration on Thursday announced the results of negotiations between Medicare and pharmaceutical companies over the prices of 10 costly or common medications. The new prices, which will take effect in 2026, are the maximum Medicare Part D plans and patients will pay for a one-month supply.
1. Eliquis, for preventing strokes and blood clots, from Bristol Myers Squibb and Pfizer, $231
2. Jardiance, for diabetes and heart failure, from Boehringer Ingelheim and Eli Lilly, $197
3. Xarelto, for preventing strokes and blood clots, from Johnson & Johnson, $197
4. Januvia, for diabetes, from Merck, $113
5. Farxiga, for diabetes, heart failure and chronic kidney disease, from AstraZeneca $178
6. Entresto, for heart failure, from Novartis, $295
7. Enbrel, for autoimmune conditions, from Amgen, $2,355
8. Imbruvica, for blood cancers, from AbbVie and Johnson & Johnson, $9,319
9. Stelara, for autoimmune conditions, from Johnson & Johnson, $4,695
10. Fiasp and NovoLog insulin products, for diabetes, from Novo Nordisk, $119
Noah Weiland writes about health care for The Times. More about Noah Weiland
Rebecca Robbins is a reporter covering the pharmaceutical industry. She has been reporting on health and medicine since 2015. More about Rebecca Robbins
See more on: U.S. Politics, President Joe Biden
- Share full article
SKIP ADVERTISEMENT
Source: nytimes.com
